Get started
Author

Marion Drouin

C-Type Lectin-Like Receptors: Head or Tail in Cell Death Immunity
2020 · Marion Drouin, Javier Saenz, et al. · Frontiers in Immunology · 140
PDF
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
2022 · Marion Drouin, Javier Saenz, et al. · Science Advances · 25
PDF
CLEC-1 Restrains Acute Inflammatory Response and Recruitment of Neutrophils following Tissue Injury
2024 · Camille Ligeron, Javier Saenz, et al. · The Journal of Immunology · 7
Abstract 3259: CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy controlling damaged and tumor cells phagocytosis
2020 · Vanessa Gauttier, Marion Drouin, et al. · Cancer Research · 1
Abstract 7293: First in class Anti-CLEC-1A myeloid checkpoint antibodies for the treatment of solid tumors with monotherapy and combination therapy efficacies
2025 · Etienne Foucher, Mylène Deramé, et al. · Cancer Research
Abstract 6342: Anti-tumor in vivo efficacy of different classes of anti-CLEC-1 myeloid checkpoint antibodies in monotherapy and in combination with chemotherapeutic agents
2024 · Aurore Morello, Mylène Deramé, et al. · Cancer Research
493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoralin vivoefficacies in humanized preclinical models
2023 · Irène Baccelli, Caroline Mary, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 6358: CLEC-1 inhibitory myeloid checkpoint blockade enhances antitumor responses and tumor phagocytosis by macrophages
2023 · Vanessa Gauttier, Irène Baccelli, et al. · Cancer Research
Abstract 6365: TRIM21 is a novel endogenous partner of the inhibitory myeloid checkpoint CLEC-1 involved in tumor antigen cross-presentation
2023 · Irene Baccelli, Vanessa Gauttier, et al. · Cancer Research
484 Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation
2022 · Vanessa Gauttier, Marion Drouin, et al. · Journal for ImmunoTherapy of Cancer
PDF
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
2022 · Javier, Saenz, Drouin Marion, et al. · Zenodo (CERN European Organization for Nuclear Research)
Etudier le rôle de CLEC-1 un nouveau récepteur inhibiteur des cellules myéloïdes et son application thérapeutique en cancérologie
2021 · Marion Drouin · theses.fr (ABES)
230 Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology
2021 · Vanessa Gauttier, Marion Drouin, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 1636: CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation
2021 · Vanessa Gauttier, Sabrina Pengam, et al. · Cancer Research
212 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies
2020 · Vanessa Gauttier, Marion Drouin, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 3423: CLEC-1 suppress dendritic cell antigen presentation and is a novel myeloid immune checkpoint target for cancer immunotherapy
2020 · Marion Drouin, Javier Saenz, et al. · Cancer Research
Works count: 16
Citation count: 173
H-index: 3
I10-index: 2
Year
Topic
Type